Thrombotic Microangiopathy
14
1
2
5
Key Insights
Highlights
Success Rate
63% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
21.4%
3 terminated out of 14 trials
62.5%
-24.1% vs benchmark
21%
3 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (14)
A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
Therapeutic Orientation Test in Thrombotic Microangiopathy
Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic Microangiopathy
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
N-Acetylcysteine as Therapy for Transplantation- Associated Thrombotic Microangiopathy
Thrombotic Microangiopathy (TMA) Associated With Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adult Patients
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy